The lawsuit, filed by former Genzyme shareholders in 2015, alleged Sanofi intentionally slowed development of Lemtrada, Genzyme’s MS drug, to avoid paying the shareholders for regulatory and sales milestones.
The shareholders said they were due between $708 million and $3.8 billion depending on how quickly Lemtrada received FDA approval, according to BioPharma Dive.
The settlement does not include an admission of liability or wrongdoing from Sanofi.
Read the full article here.
More articles on pharmacy:
Amgen exits neuroscience research, cuts 180 US jobs
Walgreens’ exit from health clinic business should serve as a warning to rivals
Top 10 pharmacy stories in October
